CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases release_ish7dxnw6bcrnockcfrgbfbzta [as of editgroup_5fxc56whcjcw5f5rmlfw6jqktu]

by Ansar Karimian, Negar Gorjizadeh, Forough Alemi, Zatollah Asemi, Khalil Azizian, Jafar Soleimanpour, Faezeh Malakouti, Niloufar Targhazeh, Maryam Majidinia, Bahman Yousefi

Published in Life Sciences by Elsevier BV.

2020   p118165

Abstract

CRISPR (clustered regularly interspaced short palindromic Repeats)/Cas9 is a new genetic editing technology that can be a beneficial method to advance gene therapy. CRISPR technology is a defense system of some bacteria against invading viruses. Genome editing based on the CRISPR/Cas9 system is an efficient and potential technology that can be a viable alternative to traditional methods. This system is a compound of a short guide RNAs (gRNAs) for identifying the target DNA sequence and Cas9 protein as nuclease for breaking and cutting of DNA. In this review, recent advances in the CRISPR/Cas9-mediated genome editing tools are presented as well as their use in gene therapy strategies for the treatment of neurological disorders including Parkinson's disease, Alzheimer's disease, and Huntington's disease.
In text/plain format

Archived Content

There are no accessible files associated with this release. You could check other releases for this work for an accessible version.

Type  article-journal
Stage   published
Date   2020-07-28
Language   en ?
Container Metadata
Not in DOAJ
In Keepers Registry
ISSN-L:  0024-3205
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 0333cabf-f71c-4777-8cbd-896e88099ceb
API URL: JSON